Navigation Links
AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Date:9/1/2009

QUEBEC CITY, Sept. 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, M.D., will present a corporate overview at the upcoming Rodman Renshaw Annual Global Investment Conference on Wednesday, September 9, 2009 at 12:30 p.m. (eastern time) in the Spellman Salon (5th floor) of the New York Palace Hotel in New York City.

A live webcast of the presentation will be available on AEterna Zentaris' website at www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
4. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
5. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
6. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
7. AEterna Zentaris Receives US$10 Million from Institutional Investors
8. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
9. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
11. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions ... scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... experience providing advanced instruments and applications consulting for microscopy and surface analysis, ... in application consulting, Nanoscience Analytical offers a broad range of contract analysis ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):